Pfizer Reports Positive Results For Rheumatoid Arthritis

Pfizer has announced that data from two new mid-stage clinical studies of oral JAK-3 inhibitor, CP-690,550, showed statistically significant response, versus placebo for patients with rheumatoid arthritis (RA).

CP-690,550 is an oral, selective, potent inhibitor of the JAK family of enzymes, which are involved in numerous inflammatory and autoimmune diseases, including RA.

Data from these two phase-II trials and one ongoing open-label safety study, will be presented this week at the 10th Annual Congress of the European League Against Rheumatism (EULAR). These results confirm findings from two previously reported Phase-II studies in RA and have been used to support dose selection for Phase-III.